Concepedia

Charles Schweizer

CS

Statistics

Publications

17

Citations

885

H-Index

15

Active since

1977

Affiliations

Morphotek (United States)(Current)

National Cancer Institute

Memorial Sloan Kettering Cancer Center

National Institutes of Health

Johns Hopkins University

Charles Schweizer is an author at Morphotek (United States) specializing in oncology, medicine, and pharmacology.

Publications per year

1977–2020

17

Publications

17

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

Raffit Hassan, Steven J. Cohen, Martin D. Phillips et al. · Clinical Cancer Research · 2010 · 200 citations · Full text

, , +17

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse

Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia et al. · Journal of Clinical Oncology · 2016 · 159 citations · Full text

, , +17

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study

Jason Konner, Katherine M. Bell‐McGuinn, Paul Sabbatini et al. · Clinical Cancer Research · 2010 · 158 citations

, , +16

Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

Raffit Hassan, Charles Schweizer, Kun F. Lu et al. · Lung Cancer · 2009 · 84 citations · Full text

, , +11

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Kenneth H. Kim, Danijela Jelovac, Deborah K. Armstrong et al. · Gynecologic Oncology · 2015 · 35 citations · Full text

, , +15

1–5 of 17